David Dornan
Förmögenhet: 1 917 $ per 2025-06-30
Förmögenhet: 1 917 $ per 2025-06-30
David Dornan is Chief Scientific Officer at Whitehawk Therapeutics, Inc. since 2025.
Former roles include Chief Scientific Officer at Elevation Oncology, Inc. from 2022 to 2025, Senior Vice President-Research & Manufacturing at Bolt Biotherapeutics, Inc. from 2019 to 2022, and Director & Head-Oncology Research at Gilead Sciences, Inc. from 2012 to 2017.
Education includes a doctorate from the University Of Dundee and an undergraduate degree from the University of Strathclyde.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
ELEVATION ONCOLOGY, INC. 0,01 % | 2025-03-31 | 5 223 ( 0,01 % ) | 1 917 $ | 2025-06-30 |
| Företag | Position | Start |
|---|---|---|
| WHITEHAWK THERAPEUTICS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2025-02-18 |
| Företag | Position | Slut |
|---|---|---|
| ELEN ONCO | Teknisk/Vetenskaplig/F&U Direktör | 2025-02-17 |
| BOLT BIOTHERAPEUTICS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2022-03-11 |
| GILEAD SCIENCES, INC. | Direktör/Styrelseledamot | 2017-11-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 6 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
University Of Dundee
University Of Dundee Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strathclyde
University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Elevation Oncology, Inc.
Elevation Oncology, Inc. BiotechnologyHealth Technology Develops elevating precision medicines for cancer treatment | Health Technology |
Aadi Bioscience, Inc.
Aadi Bioscience, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån